Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Liver Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Urothelial Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

Dexamethasone 28 Rituximab 16 pomalidomide 13 Gemcitabine 12 Lenalidomide 11 Cisplatin 11 Bortezomib 11 Paclitaxel 10 Cyclophosphamide 8 Carboplatin 8 carfilzomib 7 selinexor 5 daratumumab 5 Drug Therapy 5 Doxorubicin 5 Cytarabine 5 ibrutinib 4 Vincristine 4 Temozolomide 4 Prednisone 4 Docetaxel 4 Calcium Dobesilate 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Cetuximab 3 Bendamustine Hydrochloride 3 venetoclax 2 ofatumumab 2 galiximab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × tremelimumab × Clear all

NCT02369874 2021-02-10

EAGLE

AstraZeneca

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡